107 related articles for article (PubMed ID: 17387689)
81. The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.
Sen S; West AB
Antioxid Redox Signal; 2009 Sep; 11(9):2167-87. PubMed ID: 19271991
[TBL] [Abstract][Full Text] [Related]
82. What causes cell death in Parkinson's disease?
Gupta A; Dawson VL; Dawson TM
Ann Neurol; 2008 Dec; 64 Suppl 2(0 2):S3-15. PubMed ID: 19127586
[TBL] [Abstract][Full Text] [Related]
83. Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy.
Ubhi K; Rockenstein E; Mante M; Patrick C; Adame A; Thukral M; Shults C; Masliah E
Neuroreport; 2008 Aug; 19(13):1271-6. PubMed ID: 18695506
[TBL] [Abstract][Full Text] [Related]
84. Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?
Bogaerts V; Theuns J; van Broeckhoven C
Genes Brain Behav; 2008 Mar; 7(2):129-51. PubMed ID: 17680806
[TBL] [Abstract][Full Text] [Related]
85. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro.
Ono K; Yamada M
J Neurochem; 2006 Apr; 97(1):105-15. PubMed ID: 16524383
[TBL] [Abstract][Full Text] [Related]
86. Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's beta-amyloid fibrils in vitro.
Ono K; Hasegawa K; Naiki H; Yamada M
Neurochem Int; 2006 Mar; 48(4):275-85. PubMed ID: 16343694
[TBL] [Abstract][Full Text] [Related]
87. Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro.
Hirohata M; Ono K; Morinaga A; Yamada M
Neuropharmacology; 2008 Mar; 54(3):620-7. PubMed ID: 18164319
[TBL] [Abstract][Full Text] [Related]
88. Vitamin A potently destabilizes preformed alpha-synuclein fibrils in vitro: implications for Lewy body diseases.
Ono K; Yamada M
Neurobiol Dis; 2007 Feb; 25(2):446-54. PubMed ID: 17169566
[TBL] [Abstract][Full Text] [Related]
89. Anti-fibrillogenic and fibril-destabilizing activity of nicotine in vitro: implications for the prevention and therapeutics of Lewy body diseases.
Ono K; Hirohata M; Yamada M
Exp Neurol; 2007 Jun; 205(2):414-24. PubMed ID: 17425956
[TBL] [Abstract][Full Text] [Related]
90. Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro.
Ono K; Hirohata M; Yamada M
J Neurosci Res; 2007 May; 85(7):1547-57. PubMed ID: 17387689
[TBL] [Abstract][Full Text] [Related]
91. Alpha-synuclein assembly as a therapeutic target of Parkinson's disease and related disorders.
Ono K; Hirohata M; Yamada M
Curr Pharm Des; 2008; 14(30):3247-66. PubMed ID: 19075704
[TBL] [Abstract][Full Text] [Related]
92. [Molecular mechanisms of the neuroprotective effect of (-)-deprenyl].
Pálfi M; Szökó E; Kálmán M
Orv Hetil; 2006 Jul; 147(27):1251-7. PubMed ID: 16927880
[TBL] [Abstract][Full Text] [Related]
93. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.
Uversky VN
J Neurochem; 2007 Oct; 103(1):17-37. PubMed ID: 17623039
[TBL] [Abstract][Full Text] [Related]
94.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
95.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
96.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
97.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
98.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
99.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
